Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities

CNU IR > College of Smart Living > Dept. of Hospital and Health (including master's program) > Periodical Articles > Item 310902800/34525

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34525

题名:	Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities
作者:	Wu, Nan-Chun Feng, Yin-Hsun Kuo, Yu Hsuan Chen, Wei-Yu Wu, Hong-Chang Huang, Chien-Tai Wang, Wen-Ching Kang, Nai-Wen Shih, Jhih-Yuan Chen, Zhih-Cherng Chang, Wei-Ting
贡献者:	Chi Mei Hospital Chia Nan University of Pharmacy & Science, Department of Hospital and Health Care Administration Chi Mei Hospital Chi Mei Hospital Chi Mei Hospital Chia Nan University of Pharmacy & Science Southern Taiwan University of Science & Technology National Cheng Kung University
关键词:	cancer-patients myocarditis mechanisms cardiology management diagnosis therapy
日期:	2022
上传时间:	2023-12-11 13:55:40 (UTC+8)
出版者:	TAIWAN SOC CARDIOLOGY
摘要:	Background: Despite the increasing prevalence of therapies utilizing immune checkpoint inhibitors (ICIs), the associated cardiovascular complications have been poorly reported. Given the fatality of ICI-related complications, especially myocarditis, optimal risk stratification to predict major adverse cardio- and cerebrovascular events (MACCEs) in patients receiving ICIs is mandatory. Methods: We collected clinical data from patients receiving ICIs, and the primary outcomes were MACCEs, including myocarditis, heart failure, and ischemic stroke. Other systemic immune responses relating to ICIs were also recorded. The median follow-up duration was 3 years. Results: Among 580 patients, the incidence of MACCEs was 3.9%. Older patients, male patients, and patients with lung cancer, liver cirrhosis, or diabetes had higher risks of MACCEs. There was no significant difference between the use of PD-1/PD-L1 inhibitors or CTLA inhibitors in terms of developing cardiovascular toxicities. The development of ICI-related MACCEs was associated with worse survival. Notably, after re-review, by specialists, three patients eventually diagnosed with ICI-related myocarditis had not previously been identified. Only one was treated with pulse steroids, and none survived. The most common concomitant extracardiac immune-related adverse events were myositis/dermatitis, endocrine toxicity and hepatitis. Conclusions: Collectively, ICIs may lead to severe cardiovascular toxicities and require more attention. Early identification, proper diagnosis and prompt treatment are pivotal for improving survival.
關聯:	Acta Cardiologica Sinica, v.38, pp.:39-46
显示于类别:	[Dept. of Hospital and Health (including master's program)] Periodical Articles

文件中的档案:

档案	描述	大小	格式	浏览次数
acs-38-039.pdf		262Kb	Adobe PDF	122	检视/开启
index.html		0Kb	HTML	365	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....